ד"ר מרים הורביץ - פריד

אוניברסיטת בר אילן

1997-1999 B.Sc  ביולוגיה תאית ומולקולרית , בהצטינות

2000-2002 M.Sc ביוטכנולוגיה , בהצטיינות

נושא התזה :

               "Insulin-induced glucose uptake in L8 skeletal muscle:  

                      importance of PKC Delta 

Expression regulation of ביולוגיה מולקולרית. נושא התזה:   PhD 2003-2007  isoenzyme from PKC family by insulin in skeletal  muscle

פרסים ומלגות

2003-2007 : “President’s Scholarships for Outstanding Doctoral Students” program at Bar-Ilan University.

2005-2006:  Scholarship for" encourage excellence in research" .  faculty of life Science, Bar-Ilan university.

1999: Scholarship for excellence in studies . faculty of life Science, Bar-Ilan university

2007-2008:  Research fellowship in  lab of cellular biology headed by Prof. Sanford   Sampson , Bar-Ilan university. Responsibilities: involvement  in all aspects of the scientific research, including guiding graduate students, take part  in  writing articles and grants combined with leading my independent research

2008-2009 : review of biology and chemistry patent files, T. Colb office

2008-2017: lab manager in Laboratory of Tumor Immunology and  Immunotherapy headed by Prof. Cyrill Cohen. Bar-Ilan University Responsibilities: As a laboratory manager, I was involved in all aspects of the scientific research, including guiding graduate students, take part  in  writing articles   and grants,   and also responsibility of  the  technical aspects of lab management

               2017-present:  Researcher in  laboratory  of  Immune Gene Editing, headed by Prof. Adi   Barzel . School of biochemistry and molecular biology, faculty of life science,  Tel-Aviv university

תחומי התמחות: אימונולוגיה, אימונותרפיה, ביולוגיה מולקולרית ותאית

תחומי הוראה: ביולוגיה בסיסית: אנטומיה ופיזיולוגיה של מערכות הגוף, פתלוגיה ופזיולוגיה מתקדמת, אנדוקרינולוגיה, רגולציה של ביטוי גנים.

שיטות בביולוגיה תאית, ביוכימיה, ביולוגיה מולקולרית, אימונולוגיה, אימונותרפיה, התמיינות תאי גזע, הנדסת תאים

Horovitz-Fried M., Brand C., Cipok M., Bak A., Inbar A., Patel N., Cooper D.R., Sampson R.S. Insulin rapidly upregulates protein kinase C delta gene expression. Cell Signaling, Feb 2006;18(2):183-93. (IF: 4.305, Citations: 17, Q1)

Horovitz-Fried M., Jacob A., Cooper D.R., Sampson R.S. Activity of the Nuclear Transcription Factor SP-1 by Insulin rapidly Increases the Expression of Protein Kinase C Delta in Skeletal Muscle. Cell Signaling, Mar 2007;19(3):556-62. (IF: 4.305, Citations: 20, Q1)

Horovitz-Fried M., Sampson R.S. PKCα Involved in Insulin-Induced PKCδ Expression: Importance of SP-1 and NFκB Transcription Factors. BBRC, 352 (2007):78-83. (IF: 2.648, Citations: 19, Q1)

Horovitz-Fried M., Brutman-Barazani T., Kesten D., Sampson R.S. Insulin Increases Nuclear PKCδ in L6 Skeletal Muscle. Endocrinology, Apr 2008;149(4):1718-27. (IF: 4.276, Citations: 15, Q1)

Jacob A.I., Horovitz-Fried M., Aga-Mizrachi S., Brutman-Barazani T., Okhrimenko H., Zick Y., Brodie C., Sampson S.R. The regulatory domain of protein kinase C delta positively regulates insulin receptor signaling. J Mol Endocrinol, Mar 2010;44(3):155-69. (IF: 3.081, Citations: 13, Q1)

Bialer G., Horovitz-Fried M., Ya'acobi S., Morgan R.A., Cohen C.J. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol, Jun 2010;184(11):6232-41. (IF: 5.185, Citations: 69, Q1)

S.R. Sampson, E. Bucris, M. Horovitz-Fried, A. Parnas, S. Kahana, G. Abitbol, M. Chetboun, T. Rosenzweig, C. Brodie, S. Frankel. Insulin Increases Apoptosis in Pancreatic Beta (β) Cells. Apoptosis, Oct 2010;15(10):1165-76. (IF: 3.967, Citations: 24, Q1)

Brand C., Horovitz-Fried M., Inbar A., Tamar-Brutman-Barazani, Brodie C., Sampson S.R. Insulin stimulation of PKCδ triggers its rapid degradation via the ubiquitin-proteasome pathway. Biochim Biophys Acta, Nov 2010;1803(11):1265-75. (IF: 3.062, Citations: 13, Q1)

Brutman-Barazani T., Horovitz-Fried M., Aga-Mizrachi S., Brand C., Brodie C., Rosa J., Sampson S.R. Protein kinase Cδ but not PKCα is involved in insulin-induced glucose metabolism in hepatocytes. J Cell Biochem, Jun 2012;113(6):2064-76. (IF: 3.062, Citations: 14, Q1)

Haga-Friedman A., Horovitz-Fried M., Cohen C.J. Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity. J Immunol, Jun 2012;188(11):5538-46. (IF: 5.185, Citations: 22, Q1)

Daniel-Meshulam I., Horovitz-Fried M., Cohen C.J. Enhanced anti-tumor activity mediated by human 4-1BB-engineered T-cells. Int J Cancer, Dec 2013;133(12):2903-13. (IF: 5.531, Citations: 15, Q1)

Ankri C., Shamalov K., Horovitz-Fried M., Mauer S., Cohen C.J. Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. J Immunol, Oct 2013;191(8):4121-9. (IF: 5.185, Citations: 39, Q1)

Tal Y., Yaakobi S., Horovitz-Fried M., Safyon E., Rosental B., Porgador A., Cohen C.J. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget, Nov 2014;5(21):10949-58. (IF: 6.359, Citations: 8, Q1)

Rinat Meir, Katerina Shamalov, Oshra Betzer, Menachem Motiei, Miryam Horovitz-Fried, Ronen Yehuda, Aron Popovtzer, Rachela Popovtzer, Cyrille J. Cohen. Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T‑Cells in Vivo with Gold Nanoparticles and CT Imaging. ACS Nano, Jun 2015. (IF: 13.709, Citations: 11, Q1)

Cyrille J. Cohen, Jared J. Gartner, Miryam Horovitz-Fried, Katerina Shamalov, Kasia Trebska-McGowan, Valery Bliskovsky, Maria R. Parkhurst, Chen Ankri, Todd D. Prickett, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Steven A. Rosenberg, Paul F. Robbins. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest, Oct 2015;125(10):3981-91. (IF: 13.25, Citations: 67, Q1)

Shamalov K., Levy S.N., Horovitz-Fried M., Cohen C.J. The mutational status of p53 can influence its recognition by human T-cells. Oncoimmunology, Jan 2017;6(4). (Citations: 8, Q1)

Kesten D., Horovitz-Fried M., Brutman-Barazani T., Sampson S.R. Insulin-induced translocation of IR to the nucleus in insulin responsive cells requires a nuclear translocation sequence. Biochim Biophys Acta, Apr 2018;1865(4):551-559. (IF: 2.648, Citations: 18, Q1)

Alessio D. Nahmad, Yuval Raviv, Miriam Horovitz-Fried, Ilan Sofer, Tal Akriv, Daniel Nataf, Iris Dotan, Yaron Carmi, David Burstein, Yariv Wine, Itai Benhar, Adi Barzel. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nature Communications, Nov 2020;11:5851. (IF: 14.919, Citations: 15, Q1)

Alessio David Nahmad, Cicera Lazzarotto, Natalie Zelikson, Talia Kustin, Mary Tenuta, Deli Huang, Inbal Reuveni, Miriam Horovitz-Fried, Iris Dotan, Rina Rosin-Arbesfeld, David Nemazee, James Voss, Adi Stern, Shengdar Tsai, Adi Barzel. In-vivo engineering of B cells elicits memory retention and allows for secretion of broadly neutralizing antibodies in mice. J Immunol, May 2021;206. (IF: 1.96, Q1)

A.D. Nahmad, C.R. Lazzarotto, N. Zelikson, D. Huang, I. Reuveni, M. Horovitz-Fried, I. Dotan, A. Barzel. In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice. Nature Biotechnology, received Jun 2022; NBT-RA53459B. (SJR: 20.12, Q1)

A.D. Nahmad, E. Reuveni, E. Goldschmidt, T. Tenne, M. Liberman, M. Horovitz-Fried, R. Khosravi, H. Kobo, E. Reinstein, A. Madi, U. Ben-David, A. Barzel. Frequent Aneuploidy in Primary Human T Cells Following CRISPR-Cas9 cleavage. Nature Biotechnology, received May 2022; NBT-RA54934A. (SJR: 20.12, Q1)

• Patent Application No. 17/200,357 – Continuation-in-part of PCT/IL2019/051026: "Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion"

• European Patent Application No. 18786980.5 – "Recombination activating gene (RAG) induced V(D)J gene targeting" | 2017019-02

• United States Provisional Patent Application No. 63/324,284 – "Site-specific in vivo T cell engineering, systems, compositions and methods thereof" (Ref: 2022008-00)

עברית - שפת אם

אנגלית